Neoadjuvant Darovasertib in Primary Uveal Melanoma
Recruiting now Phase 3 NCT07015190
Run by IDEAYA Biosciences · for 18 and older · All sexes
What this study is about
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Who can join (things the study team will check)
✅ You may be able to join if…
- Primary non-metastatic uveal melanoma
- Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
- ECOG 0 or 1
- Adequate organ function
🚫 You may not be able to join if…
- Previous treatment for UM
- Evidence of metastatic UM
- Attributes that necessitate enucleation regardless of response to therapy
- Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
- Presence of a malignant disease other than the one being treated in this study
Where this trial is running
- Mayo Clinic Scottsdale - PPDS, Scottsdale, Arizona, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- Jules Stein Eye Institute, Los Angeles, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Irvine Medical Center, Orange, California, United States
- Stanford Comprehensive Cancer Center, Palo Alto, California, United States
- Kaiser Permanente-Riverside Medical Center, Riverside, California, United States
- UCSF Wayne and Gladys Valley Center for Vision, San Francisco, California, United States
- University of Colorado Hospital, Aurora, Colorado, United States
- The Melanoma and Skin Cancer Institute, Englewood, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- USF Health Eye Institute, Tampa, Florida, United States
+ 82 more sites.
Who to contact
IDEAYA Clinical Trials · +1-855-433-2246 · IDEAYAClinicalTrials@ideayabio.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07015190.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.